C-myc repression of TSC2 contributes to control of translation initiation and myc-induced transformation

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11209-11217

  Ravitz, Michael J ^a   Chen, Li ^a   Lynch, Mary ^a   Schmidt, Emmett V ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MYC PROTEIN; S6 KINASE; SHORT HAIRPIN RNA; TUBERIN;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; GENE CONTROL; GENE REPRESSION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RIBOSOME SUBUNIT; RNA ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; MICE, KNOCKOUT; MUTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; POLYRIBOSOMES; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RIBOSOMAL PROTEIN S6; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 37049024761     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4351     Document Type: Article

References (43)

1. Baserga R. The biology of cell reproduction. Cambridge (MA): Harvard University Press; 1985.
2. Hahn WC, Dessain SK, Brooks MW, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002;22:2111-23.
3. Sonenberg N, Hershey JWB, Mathews M, editors. Translational control of gene expression. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2000.
4. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
5. Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 1996;16:4754-64.
6. 1 transition but not for the G1/S transition. Proc Natl Acad Sci U S A 2006;103:2695-700.
7. Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004;4:289-302.
8. Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004;23:3217-21.
9. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48.
10. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63.
11. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88.
12. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177-89.
13. Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 2003;12:271-80.
14. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.
15. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005;14 Spec No. 2:R251-8.
16. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005;24:7475-81.
17. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-16.
18. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 2001;105:345-55.
19. Rosner M, Hofer K, Kubista M, Hengstschlager M. Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene 2003;22:4786-98.
20. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003;100:8164-9.
21. Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 1997;272:29301-8.
22. Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol Chem 2004;279:3327-39.
23. You Z, Madrid LV, Saims D, Sedivy J, Wang CY. c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor κB transactivation. J Biol Chem 2002;277:36671-7.
24. Lynch M, Chen L, Ravitz MJ, et al. hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol 2005;25:6436-53.
25. Meyuhas O, Blierman Y, Pierandrei-Amaldi P, Amaldi F. Analysis of polysomal RNA. In: Krieg P, editor. A laboratory guide to RNA: isolation, analysis and synthesis. New York (NY): Wiley Liss; 1996. p. 65-81.
26. Yamashita R, Suzuki Y, Wakaguri H, Tsuritani K, Nakai K, Sugano S. DBTSS: DataBase of Human Transcription Start Sites, progress report 2006. Nucleic Acids Res 2006;34:D86-9.
27. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 2004;32:W217-21.
28. Kato GJ, Lee WM, Chen LL, Dang CV. Max: functional domains and interaction with c-Myc. Genes Dev 1992;6:81-92.
29. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 2004;279:29930-7.
30. Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 2001;98:3826-31.
31. Polymenis M, Schmidt EV. Coordination of cell growth with cell division. Curr Opin Genet Dev 1999;9:76-80.
32. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990;345:544-7.
33. Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-6.
34. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
35. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46.
36. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998;54:815-24.
37. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box Ii. EMBO J 1994;13:4070-9.
38. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001;21:5050-62.
39. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/ Tsc2 activates mTOR and disrupts PI3K-Akt signaling through down-regulation of PDGFR. J Clin Invest 2003;112:1223-33.
40. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003;38:376-81.
41. Zhang XY, DeSalle LM, Patel JH, et al. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A 2005;102:13968-73.
42. Guccione E, Martinato F, Finocchiaro G, et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006;8:764-70.
43. Kim JW, Zeller KI, Wang Y, et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 2004;24:5923-36.